1462 Objectives Neuroendocrine tumors (NET) have proven to be appropriate neoplasms
for PRRT, as the majority of these slow-growing malignancies overexpress somatostatin …

Abstract Introduction Neuroendocrine tumors (NETs) have proven to be appropriate
neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow …

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased
considerably in the last few decades. The characteristic features of this tumour and the …

Objectives The aim of this study was to analyze in a retrospective cohort study the outcomes
of a United States–based group of metastatic neuroendocrine tumor (NET) patients who …

Purpose The clinical benefit of peptide receptor radionuclide therapy (PRRT) in patients with
pancreatic neuroendocrine tumours (pNET) has not yet been well described and defined in …

43 Objectives To evaluate the response to PRRT, using Y-90 or Lu-177 DOTA-TATE) and
assess overall survival in patients with pNET. Methods 107 patients (mean age 60 yrs) of …

Peptide receptor radionuclide therapy (PRRT) is a paradigm shifting approach to the
treatment of neuroendocrine tumors. Although there are no prospective randomized trials …

Objectives The objective of this study was to describe the outcomes of patients in the
University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor …

ABSTRACT 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is now
approved for patients with advanced gastroenteropancreatic neuroendocrine tumors (NET) …

Aim/Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective and well-
tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs …